Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostat
CAS Number:
[1365287-97-3]
Target:
c-Met/HGFR
* VAT and and shipping costs not included. Errors and price changes excepted